Liminal BioSciences (LMNL) Stock Price, News & Analysis

Company Overview

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Key Stats

• Today's Range: $8.50 to $8.50
• 50-Day Range: $8.38 to $8.50
• 52-Week Range: $3.10 to $8.50
• Volume: N/A
• Average Volume: 63,470 shs
• Market Capitalization: $26.35 million
• P/E Ratio: 29.31
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LMNL Stock Analysis - Frequently Asked Questions

How were Liminal BioSciences' earnings last quarter?

Liminal BioSciences Inc. (NASDAQ:LMNL) posted its quarterly earnings results on Monday, November, 15th. The company reported $27.40 earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.80) by $30.20. The company had revenue of $0.14 million for the quarter, compared to analysts' expectations of $0.02 million. Liminal BioSciences had a negative trailing twelve-month return on equity of 88.44% and a net margin of 248.35%.

When did Liminal BioSciences' stock split?

Shares of Liminal BioSciences reverse split before market open on Wednesday, February 1st 2023. The 1-10 reverse split was announced on Wednesday, February 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Liminal BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Liminal BioSciences investors own include Corbus Pharmaceuticals (CRBP), Bionano Genomics (BNGO), HubSpot (HUBS), iBio (IBIO), Dynavax Technologies (DVAX), Diamondback Energy (FANG) and NIO (NIO).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 5/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:LMNL
• CIK: 1351172
• Web: www.liminalbiosciences.com
• Phone: 1-450-781-0115
• Fax: 1-450-781-4477
• Employees: 251
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.29
• Trailing P/E Ratio: 29.31
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $380 thousand
• Net Margins: 248.35%
• Pretax Margin: -5,729.40%
• Return on Equity: -88.44%
• Return on Assets: -64.15%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 2.78
• Quick Ratio: 2.78

Sales & Book Value

• Annual Sales: $310,000.00
• Price / Sales: 85.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.97 per share
• Price / Book: 0.95

Miscellaneous

• Outstanding Shares: 3,100,000
• Free Float: 3,036,000
• Market Cap: $26.35 million
• Optionable: Not Optionable
• Beta: 1.03